Biocartis is based in Mechelen, Belgium. It has raised $305M in total funding. Latest round: Series C.
Biocartis funding overview
Biocartis is based in Mechelen, Belgium. Biocartis has raised $305M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series C announced in October 2012. The round record for Biocartis runs through 2012; nothing later has been disclosed. Investors on record include Debiopharm Group, Philips, Johnson & Johnson Development Corporation, Wellcome Trust, Korys, Valiance and 3 others. 9 distinct backers are named across the disclosed rounds.
Biocartis at a glance
Total raised
$305M
Latest round
Series C
Latest round date
October 2012
Headquarters
Mechelen, Belgium
Notable investors
Debiopharm Group, Philips, Johnson & Johnson Development Corporation, Wellcome Trust, Korys, Valiance, Biovest, PMV
Frequently asked about Biocartis funding
How much has Biocartis raised?
Biocartis has raised $305M in total disclosed funding across the rounds on record.
Who has invested in Biocartis?
Debiopharm Group, Philips, Johnson & Johnson Development Corporation, Wellcome Trust, Korys, Valiance are named among the investors backing Biocartis.
What was the latest Biocartis funding round?
The most recent disclosed round is a Series C, announced in October 2012.
Where is Biocartis based?
Biocartis is based in Mechelen, Belgium.
When did Biocartis last raise?
The last disclosed Biocartis round closed in October 2012 at Series C.
Totals shown for Biocartis aggregate every disclosed round on file. To see how that compares, browse the companies in Mechelen and the investors behind them below.
